A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
Clinical trial NCT05374512 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05374512
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-16
- Primary completion
- 2025-08-25
- Enrollment
- 644
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.